An XMRV Derived Retroviral Vector as a Tool for Gene Transfer
© Cervantes-Garcia et al; licensee BioMed Central Ltd. 2011
Received: 20 May 2011
Accepted: 8 June 2011
Published: 8 June 2011
Retroviral vectors are widely used tools for gene delivery and gene therapy. They are useful for gene expression studies and genetic manipulation in vitro and in vivo. Many retroviral vectors are derived from the mouse gammaretrovirus, murine leukemia virus (MLV). These vectors have been widely used in gene therapy clinical trials. XMRV, initially found in prostate cancer tissue, was the first human gammaretrovirus described.
We developed a new retroviral vector based on XMRV called pXC. It was developed for gene transfer to human cells and is produced by transient cotransfection of LNCaP cells with pXC and XMRV-packaging plasmids.
We demonstrated that pXC mediates expression of inserted transgenes in cell lines. This new vector will be a useful tool for gene transfer in human and non-human cell lines, including gene therapy studies.
Retroviral vectors offer a highly efficient method of stable gene transfer in mammalian cells due to their ability to integrate into the host genome [1, 2]. Moreover, the common genetic architecture of most retroviruses allows the development of similar retroviral vectors with different potentials for cell entry via virus-specific receptors and different capabilities for gene expression mediated by diverse retroviral promoters .
Current retroviral vectors used for gene transfer are replication defective. Trans-expression of retroviral structural proteins from non vector-homologous plasmids avoids the production of replication competent retrovirus (RCR) [4, 5]. Many retroviral vectors are derived from murine leukemia virus (MLV) in both, ecotropic and amphotropic versions [6, 7]. Lentiviral vectors based on HIV may offer advantages because of their lower insertion frequency in crucial loci involved in cell growth regulation and their ability to transduce non-dividing cells [8, 9]. Nevertheless, MLV-derived retroviral vectors have been used extensively, including in more than 300 gene therapy clinical trials . In addition, retroviral vectors derived from avian sarcoma leukosis virus (ASLV; ), spleen focus-forming virus (SFFV; ), and Mason-Pfizer monkey virus (MPMV; ), have been developed among others.
In 2006, the xenotropic murine-leukemia-virus related gammaretrovirus (XMRV) was discovered in a subset of human prostate cancer (PCa) tissue samples . Subsequently, additional studies demonstrated that XMRV uses the XPR1 receptor to initiate infection, and that the virus is sensitive to IFN-β and RNase-L, a final effector of the IFN-β mediated antiviral response . Since XMRV shows the basic structure of gammaretroviruses, we developed a panel of packaging plasmids and retroviral vectors derived from XMRV. Here we demonstrate their potential use as gene transfer vectors for in vitro assays.
Oligonucleotide primers used in this study.
Luciferase expression plasmid
Packaging plasmid gag-pol
Packaging plasmid env
Many retroviral vectors for gene transfer are derived from murine gamma-retroviruses. Nevertheless, to our knowledge, the pXC vector and its associated cell packaging system described here constitute the first retroviral vector system for gene transfer based on a likely human gammaretrovirus, with particular tropism for human cells and tissues. Our results suggest that the pXC vector is a useful tool for gene transfer in human cells and it is possible that this vector will contribute to elucidation of the interactions of XMRV and its human host. In addition, this new XMRV-derived retroviral vector has the potential to be used for stable transfection of human cells and for preclinical studies of gene therapy.
We thank UC-MEXUS CONACyT for support of this study with grant number CN08-229. We also thank Drs. Sandra and Francis Ruscetti, and Dr. John Elder, for providing primary antibodies.
- Page KA, Landau NR, Littman DR: Construction and use of a human immunodeficiency virus vector for analysis of virus infectivity. J Virol 1990, 64:5270–5276.PubMed
- Thomas CE, Ehrhardt A, Kay MA: Progress and problems with the use of viral vectors for gene therapy. Nat Rev Genet 2003, 4:346–358.PubMedView Article
- Hu WS, Pathak VK: Design of retroviral vectors and helper cells for gene therapy. Pharmacol Rev 2000, 52:493–511.PubMed
- Kim S, Park EJ, Yu SS, Kim S: Development of enzyme-linked immunosorbent assay for detecting antibodies to replication-competent murine leukemia virus. J Virol Methods 2004, 118:1–7.PubMedView Article
- Sinn PL, Sauter SL, McCray PB Jr: Gene therapy progress and prospects: development of improved lentiviral and retroviral vectors-design, biosafety, and production. Gene Ther 2005, 12:1089–1098.PubMedView Article
- Xu L, O'Malley T, Sands MS, Wang B, Meyerrose T, Haskins ME, Ponder KP: In vivo transduction of hematopoietic stem cells after neonatal intravenous injection of an amphotropic retroviral vector in mice. Mol Ther 2004, 10:37–44.PubMedView Article
- Koch P, Siemen H, Biegler A, Itskovitz-Eldor J, Brüstle O: Transduction of human embryonic stem cells by ecotropic retroviral vectors. Nucleic Acids Res 2006, 34:e120.PubMedView Article
- D'Costa J, Mansfield SG, Humeau LM: Lentiviral vectors in clinical trials: Current status. Curr Opin Mol Ther 2009, 11:554–564.PubMed
- Pluta K, Kacprzak MM: Use of HIV as a gene transfer vector. Acta Biochim Pol 2009, 56:531–595.PubMed
- Gene Therapy Clinical Trials Worldwide [http://www.wiley.com//legacy/wileychi/genmed/clinical/]
- Torne-Celer C, Moreau K, Faure C, Verdier G, Ronfort C: An improved self-deleting retroviral vector derived from avian leukemia and sarcoma virus. Arch Virol 2008, 153:2233–2243.PubMedView Article
- Marusich EI, Parveen Z, Strayer D, Mukhtar M, Dornburg RC, Pomerantz RJ: Spleen necrosis virus-based vector delivery of anti-HIV-1 genes potently protects human hematopoietic cells from HIV-1 infection. Virology 2005, 332:258–271.PubMedView Article
- Guesdon FM, Greatorex J, Rhee SR, Fisher R, Hunter E, Lever AM: Sequences in the 5' leader of Mason-Pfizer monkey virus which affect viral particle production and genomic RNA packaging: development of MPMV packaging cell lines. Virology 2001, 288:81–88.PubMedView Article
- Urisman A, Molinaro RJ, Fischer N, Plummer SJ, Casey G, Klein EA, Malathi K, Magi-Galluzzi C, Tubbs RR, Ganem D, Silverman RH, DeRisi JL: Identification of a novel Gammaretrovirus in prostate tumors of patients homozygous for R462Q RNASEL variant. PLoS Pathog 2006,2(3):e25.PubMedView Article
- Dong B, Kim S, Hong S, Das Gupta J, Malathi K, Klein EA, Ganem D, Derisi JL, Chow SA, Silverman RH: An infectious retrovirus susceptible to an IFN antiviral pathway from human prostate tumors. Proc Natl Acad Sci USA 2007, 104:1655–1660.PubMedView Article
- Bhosle S, Suppiah S, Molinaro R, Liang Y, Arnold R, Diehl W, Makarova N, Blackwell J, Petros J, Liotta D, Hunter E, Ly H: Evaluation of cellular determinants required for in vitro xenotropic murine leukemia virus-related virus entry into human prostate cancer and noncancerous cells. J Virol 2010,84(13):6288–6296.PubMedView Article
- Rodriguez JJ, Goff SP: Xenotropic murine leukemia virus-related virus establishes an efficient spreading infection and exhibits enhanced transcriptional activity in prostate carcinoma cells. J Virol 2010,84(5):2556–2562.PubMedView Article
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.